Role of vascular networks in extending glucose sensor function: Impact of angiogenesis and lymphangiogenesis on continuous glucose monitoring in vivo

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 10, 2014, Pages 3512-3522

  Klueh, Ulrike ^a   Antar, Omar ^a   Qiao, Yi ^a   Kreutzer, Donald L ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

blood and lymphatic vessels; diabetes; gene therapy; glucose sensors; wound healing

Indexed keywords

BLOOD VESSELS; GENE THERAPY; MAMMALS; MEDICAL PROBLEMS; NEURAL PROSTHESES; TISSUE;

ANTI-INFLAMMATORIES; CONTINUOUS GLUCOSE MONITORING; CONTINUOUS GLUCOSEMONITORING (CGM); IMPLANTABLE GLUCOSE SENSOR; INTERSTITIAL TISSUES; LYMPHATIC VESSELS; VASCULAR ENDOTHELIAL CELL GROWTHS; WOUND HEALING;

GLUCOSE SENSORS;

ANGIOGENIC FACTOR; GLUCOSE; VASCULOTROPIN; GLUCOSE BLOOD LEVEL; VASCULOTROPIN A;

ADENOVIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; FEMALE; GLUCOSE SENSOR; IMPLANTATION; IN VIVO STUDY; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; VASCULARIZATION; VIRAL GENE THERAPY; ANALYSIS; ANIMAL; BLOOD ANALYSIS; BLOOD VESSEL; C57BL MOUSE; GENE THERAPY; GENETICS; GLUCOSE BLOOD LEVEL; LYMPHOID TISSUE; PHYSIOLOGY; PROCEDURES; PROSTHESIS IMPLANTATION; REGRESSION ANALYSIS;

ANIMALS; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; BLOOD VESSELS; FEMALE; GENETIC THERAPY; LYMPHANGIOGENESIS; LYMPHOID TISSUE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTHESIS IMPLANTATION; REGRESSION ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906779521     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35031     Document Type: Article

References (34)

1. Novak MT, Yuan F, Reichert WM,. Modeling the relative impact of capsular tissue effects on implanted glucose sensor time lag and signal attenuation. Anal Bioanal Chem 2010; 398: 1695-1705.
2. Dungel P, Long N, Yu B, Moussy Y, Moussy F,. Study of the effects of tissue reactions on the function of implanted glucose sensors. J Biomed Mater Res A 2008; 85: 699-706.
3. Ward WK, Quinn MJ, Wood MD, Tiekotter KL, Pidikiti S, Gallagher JA,. Vascularizing the tissue surrounding a model biosensor: How localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF)? Biosens Bioelectron 2003; 19: 155-163.
4. Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF,. The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor. Diabetes Technol Ther 2004; 6: 137-145.
5. Norton LW, Koschwanez HE, Wisniewski NA, Klitzman B, Reichert WM,. Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. J Biomed Mater Res A 2007; 81: 858-869.
6. Klueh U, Dorsky DI, Kreutzer DL,. Uses of Vascular Endothelial Cell Growth Factor Gene Transfer to Enhance Biosensor Function In Vivo. Student Research Award in the Ph. D. Science Degree Candidate Category. In: 29th annual meeting of the Society for Biomaterials, Reno, Nevada, April 29-May 3, 2003. J Biomed Mater Res. 2003;67:1072-1086.
7. Klueh U, Dorsky DI, Kreutzer DL,. Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization. Biomaterials 2005; 26: 1155-1163.
8. Klueh U, Liu Z, Cho B, Ouyang T, Feldman B, Henning TP, Kaur M, Kreutzer DL,. Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol Ther. 2006; 8: 402-412.
9. Klueh U, Kaur M, Qiao Y, Kreutzer DL,. Critical role of tissue mast cells in controlling long-term glucose sensor function in vivo. Biomaterials 2010; 31: 4540-4551.
10. Klueh U, Liu Z, Feldman B, Kreutzer DL,. Importance of interleukin 1/interleukin 1 receptor antagonist in short term glucose sensor function in vivo. Diabetes Sci Technol 2010; 4: 1073-1086.
11. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Manseau EJ, et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 2002; 67: 227-237.
12. Klueh U, Liu Z, Feldman B, Henning TP, Cho B, Ouyang T, Kreutzer DL,. Metabolic biofouling of glucose sensors in vivo: role of tissue microhemorrhages. J Diabetes Sci Technol 2011; 5: 583-595.
13. Seregin SS, Amalfitano A,. Improving adenovirus based gene transfer: Strategies to accomplish immune evasion. Viruses 2010; 2: 2013-2036.
14. Cunningham DC, Stenken JA,. In Vivo Glucose Sensing. John Wiley & Sons, Inc., Hoboken, New Jersey; 2009. p 454.
15. Obermaier K, Schmelzeisen-Redeker G, Schoemaker M, Klotzer HM, Kirchsteiger H, Eikmeier H, del Re L,. Performance evaluations of continuous glucose monitoring systems: precision absolute relative deviation is part of the assessment. J Diabetes Sci Technol 2013; 7: 824-832.
16. Ismail JA, Poppa V, Kemper LE, Scatena M, Giachelli CM, Coffin JD, Murry CE,. Immunohistologic labeling of murine endothelium. Cardiovasc Pathol 2003; 12: 82-90.
17. Kovatchev B, Anderson S, Heinemann L, Clarke W,. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care 2008; 31: 1160-1164.
18. Regenfuss B, Bock F, Cursiefen C,. Corneal angiogenesis and lymphangiogenesis. Curr Opin Allergy Clin Immunol 2012; 12: 548-554.
19. Ward WK, Troupe JE,. Assessment of chronically implanted subcutaneous glucose sensors in dogs: the effect of surrounding fluid masses. Asaio J 1999; 45: 555-561.
20. Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE,. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 2006; 25: 443-447.
21. Huggenberger R, Detmar M,. The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc 2011; 15: 24-32.
22. Bobek V, Taltynov O, Pinterova D, Kolostova K,. Gene therapy of the ischemic lower limb-Therapeutic angiogenesis. Vascul Pharmacol 2006; 44: 395-405.
23. Brudno Y, Ennett-Shepard AB, Chen RR, Aizenberg M, Mooney DJ,. Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials 2013; 34: 9201-9209.
24. Davies NH, Schmidt C, Bezuidenhout D, Zilla P,. Sustaining neovascularization of a scaffold through staged release of vascular endothelial growth factor-A and platelet-derived growth factor-BB. Tissue Eng Part A 2012; 18: 26-34.
25. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK,. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
26. Lutton C, Young YW, Williams R, Meedeniya AC, Mackay-Sim A, Goss B,. Combined VEGF and PDGF treatment reduces secondary degeneration after spinal cord injury. J Neurotrauma 2012; 29: 957-970.
27. Bhardwaj U, Papadimitrakopoulos F, Burgess DJ,. A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors. J Diabetes Sci Technol 2008; 2: 1016-1029.
28. Benjamin LE,. The controls of microvascular survival. Cancer Metastasis Rev 2000; 19: 75-81.
29. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM,. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
30. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E,. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Investig 1999; 103: 159-165.
31. Carmeliet P, Jain RK,. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27.
32. Daugherty AL, Rangell LK, Eckert R, Zavala-Solorio J, Peale F, Mrsny RJ,. Sustained release formulations of rhVEGF(1)(6)(5) produce a durable response in a murine model of peripheral angiogenesis. Eur J Pharm Biopharm 2011; 78: 289-297.
33. Naderi H, Matin MM, Bahrami AR,. Review paper: critical issues in tissue engineering: biomaterials, cell sources, angiogenesis, and drug delivery systems. J Biomater Appl. 2011; 26: 383-417.
34. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM,. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.